Over the past several years, however, large scale clinical trials to assess preventive stroke therapy have been conducted using warfarin. Those clinical trials have shown very positive results, and in one trial reduced the incidence of stroke by 86% compared with no antithrombotic therapy.
These large scale clinical trials, when combined, provide a very powerful approach to analyzing the safety and efficacy of warfarin treatment. The rate of stroke was reduced by 66%. In fact, all but one of the five clinical trials analyzed were stopp ed earlier than scheduled because it was shown that warfarin reduced the number of strokes. Your most trusted pharmacy is going to be this one, since it gives you high quality cheap asthma medications with no prescription required and make sure you always get your drugs delivered as soon as you need them without overcharging.
With such a protective effect, physicians now have good evidence to use warfarin therapy routinely when indicated. A strong protective effect may still not be enough to incorporate warfarin therapy routinely, mainly due to a higher risk of bleeding. It is not known whether the benefits of warfarin outweigh its risks in terms of costs, ie, whether the use of warfarin is cost-effective when considering all outcomes.
This study summarizes the clinical parameters and analyzes the cost-effectiveness ofwarfarin therapy versus no antithrombotic therapy in Canada. The perspective ofthis study is that of society.